| 摘要 |
PCT No. PCT/CA92/00528 Sec. 371 Date Sep. 27, 1994 Sec. 102(e) Date Sep. 27, 1994 PCT Filed Dec. 3, 1992 PCT Pub. No. WO93/11159 PCT Pub. Date Jun. 10, 1993The present invention provides human interleukin-8 (IL-8) analogs that are modified in the Glu4 Leu5 Arg6 region, and have a core structure corresponding to the IL-8 (7-51) sequence are provided. These neutrophil binding analogs display altered IL-8 activities that can be exploited for therapeutic and other purposes. Such antagonists include those in which, for example, the Leu5 and/or Arg6 residues are replaced, and in which the Glu4 and/or Leu5 residues are deleted. Also provided are biologically active human interleukin-8 (IL-8) analogs comprising a core sequence that includes IL-8 (1-51), IL-8 (3-51) or IL-8 (4-51). The invention also provides pharmaceutical compositions containing the aforementioned analogs. |
